Systemic therapy for colorectal cancer: Patterns of chemotherapy and biologic therapy use in nationally representative US claims database

BioDrugs

Volumn 28, Issue 2, 2014, Pages 229-236

  Seal, Brian S ^a   Sullivan, Sean D ^b,c   Ramsey, Scott D ^b,c   Shermock, Kenneth M ^d   Ren, Jinma ^e   Kreilick, Charlie ^a   Boklage, Susan ^a   Valluri, Satish ^a   Sarma, Syam ^f   Asche, Carl V ^e,g  

^a Bayer HealthCare Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d Analysis by Design LLC   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f Syam Sarma   (United States)

^g UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PREFERRED PROVIDER ORGANIZATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SYSTEMIC THERAPY; YOUNG ADULT; COLORECTAL NEOPLASMS; ECONOMICS; FACTUAL DATABASE; PATHOLOGY; PRACTICE GUIDELINE; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; HEALTH CARE COSTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84897094951     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0073-y     Document Type: Article

References (17)

1. Bardakji Z, et al. 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer: clinical, pharmacokinetic and in vitro cytotoxicity studies. Cancer Chemother Pharmacol. 1986;18(2):140-4. (Pubitemid 17121428)
2. Buroker T, et al. Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep. 1977;61(8):1579-80. (Pubitemid 8241631)
3. Erlichman C. Fluorouracil and leucovorin for metastatic colorectal cancer. J Chemother. 1990;2(Suppl 1):38-40.
4. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 1989;63(6 Suppl):1036-44. (Pubitemid 19081270)
5. Karaca-Mandic P, et al. Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract. 2011;7(3 Suppl):e30s-7s.
6. Chu E. Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2006;6(1):13. (Pubitemid 44043995)
7. Hosoda K, et al. Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital. Gan To Kagaku Ryoho. 2010;37(5):841-5.
8. Yamada Y, et al. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs. 2012;30(4):1690-6.
9. Brenner H, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer. 2012;131(7):1649-58.
10. Cartwright T, et al. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. Clin Colorectal Cancer. 2008;7(6):390-7.
11. Carneiro BA, et al. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. Clin Colorectal Cancer. 2012;11(1):53-9.
12. Hess GP, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 2010;6(6):301-7.
13. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44. (Pubitemid 40347299)
14. Chu E, et al. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. Clin Colorectal Cancer. 2010;9(4):229-37.
15. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006;33(5 Suppl 10):S1-7. (Pubitemid 44634008)
16. Chastek B, Kulakodlu M, Valluri S, Seal B. Impact of metastatic colorectal cancer stage and number of treatment courses on patient healthcare costs and utilization. Postgrad Med. 2013;125(2):73-82.
17. National Comprehensive Cancer Network. 2012. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#site.